Last edition
News about Global Pharma
Slingshot Biosciences to Expand into UK and EU Markets
Slingshot Biosciences is expanding its operations into the United Kingdom and European Union to scale deployment of its precision-engineered synthetic cell mimic technology and accelerate cell and gene therapy as well as broader pharmaceutical development.
Global Pharma | 05/02/2026 | By News Bureau | 176
Patent Expiry Headwinds to Drive Novartis Operating Profit Down in 2026
Swiss pharmaceutical major Novartis has forecast a modest decline in operating profit for 2026, marking its first annual drop in a decade amid the looming impact of key drug patent expiries.
Global Pharma | 05/02/2026 | By Darshana | 846
Avidity Biosciences Sets Record Date for Atrium Therapeutics Spin Off Ahead of Novartis Merger
Avidity Biosciences announces February 12, 2026 as the record date for distributing Atrium Therapeutics shares to stockholders as part of its planned Novartis acquisition and cardiology spin-off.
Global Pharma | 03/02/2026 | By News Bureau | 877
WuXi Biologics and Vertex Pharmaceuticals collaborate to advance a preclinical trispecific T-cell engager targeting B-cell mediated autoimmune diseases under a global licensing agreement.
Global Pharma | 03/02/2026 | By News Bureau | 252
Trace Biosciences Secures FDA IND Clearance for First Nerve-Specific Fluorescent Imaging Agent
FDA clears IND application for LGW16-03, enabling Trace Biosciences to begin first-in-human trials of its nerve-targeted imaging agent designed to reduce accidental nerve injuries during surgery.
Global Pharma | 02/02/2026 | By News Bureau | 304
Illumina has completed its USD 350 million acquisition of SomaLogic, strengthening its multiomics portfolio and expanding large-scale proteomics capabilities to accelerate drug discovery and improve patient outcomes.
Global Pharma | 02/02/2026 | By News Bureau | 1002
FDA Approves Tenpoint Therapeutics' Yuvezzi, First Dual-Action Eye Drop for Presbyopia
The US FDA has approved Yuvezzi (carbachol and brimonidine tartrate), the first dual-agent eye drop for presbyopia, offering significant near-vision improvement with favourable tolerability.
Global Pharma | 31/01/2026 | By News Bureau | 394
China's NMPA approves Almirall's Seysara for Moderate-to-Severe Acne Treatment
China’s NMPA has approved Almirall’s Seysara (sarecycline hydrochloride), the first oral antibiotic developed specifically for acne, expanding access to innovative dermatology treatment in partnership with Sinomune.
Global Pharma | 31/01/2026 | By News Bureau | 372
IQVIA and Boehringer Ingelheim Partner on Global Commercial Data Transformation
The long-term strategic collaboration aims to modernise Boehringer Ingelheim’s global commercial data foundation, enabling scalable, advanced analytics across therapeutic areas and regions using IQVIA’s industry-leading data model.
Global Pharma | 31/01/2026 | By News Bureau | 359
Innovent Biologics’ tri-specific antibody IBI3003 has received FDA Fast Track Designation for heavily pretreated relapsed or refractory multiple myeloma, supported by promising early clinical efficacy and safety data.
Global Pharma | 27/01/2026 | By News Bureau | 293
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy